Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster - 2‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- 3What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly
- 4Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- 5Survey: Canteen Cups With Great Warm Protection Impact
- 6 US States for Fly Fishing
- Which Store is Your Decision ?
- UN torture cm'tee report flags Israel for allegedly mistreating journalists, detainees, ex-MAG
- Chris Noth responds to backlash after seemingly shading 'Sex and the City' costar Sarah Jessica Parker: 'It is not news'
- Strength training is crucial after menopause. How to make the most of your workouts
- Dominating Online Entertainment Showcasing: 7 Hints for Organizations
- ISS astronauts spy airglow and dwarf galaxy | Space photo of the day for Jan. 13, 2026
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- From Loner to Force to be reckoned with: Individual Accounts of Change
